Does an ejection fraction of 40–45% indicate heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does an EF of 40-45% Mean Heart Failure?

An ejection fraction of 40-45% does NOT automatically mean you have heart failure—it indicates heart failure with mildly reduced ejection fraction (HFmrEF) ONLY if the patient also has current or previous symptoms of heart failure plus objective evidence of elevated cardiac filling pressures. 1

Understanding the Classification

According to the 2022 AHA/ACC/HFSA guidelines, the EF range of 40-45% falls into the HFmrEF category (LVEF 41-49%), which sits between:

  • HFrEF: LVEF <40%
  • HFmrEF: LVEF 41-49%
  • HFpEF: LVEF ≥50% 2, 1

Critical Diagnostic Requirements

The diagnosis requires THREE components, not just the EF number:

  1. Classic HF symptoms and signs (dyspnea, fatigue, edema, reduced exercise tolerance)

  2. LVEF of 41-49% on echocardiography

  3. Objective evidence of elevated filling pressures, which can be demonstrated by:

    • Elevated natriuretic peptides (BNP/NT-proBNP)
    • Echocardiographic diastolic parameters (E/e' ≥15)
    • Invasive hemodynamic measurements at rest or with exercise
    • Evidence of structural heart disease (increased left atrial volume index or LV mass index) 1

Without symptoms and elevated filling pressures, an EF of 40-45% alone does not constitute a heart failure diagnosis.

Clinical Context Matters

The HFmrEF population represents 10-25% of all heart failure patients and appears to be a dynamic, transitional category 3. In community-based studies, only 12.5% of incident heart failure cases present with HFmrEF, and these patients frequently transition: 26.9% decline to HFrEF (EF ≤40%) and 44.8% improve to HFpEF range (EF ≥50%) on follow-up 4.

Key clinical features of HFmrEF patients:

  • More similar to HFpEF than HFrEF in demographics and comorbidity burden
  • High prevalence of ischemic heart disease (more similar to HFrEF in this respect)
  • Intermediate cardiovascular risk profile
  • Mean age typically mid-70s with mixed gender distribution 3, 4

Prognostic Implications

The relationship between EF and cardiovascular outcomes shows that mortality risk increases by 39% for every 10% reduction in EF below 45% 5. However, once EF rises above 45%, further increases do not substantially reduce cardiovascular risk—the risk plateaus 5. This means:

  • An EF of 40-45% carries higher risk than EF >45%
  • But the absolute risk difference between 45% and 60% is minimal
  • The critical threshold appears to be 45%, not the traditional 40% cutoff

Treatment Implications

If heart failure IS diagnosed with EF 40-45%, treat similarly to HFrEF. The guidelines recommend considering HFrEF therapies for HFmrEF patients, including:

  • ACE inhibitors or ARNIs
  • Beta-blockers
  • Mineralocorticoid receptor antagonists
  • SGLT2 inhibitors 2, 3, 6

Evidence from post-hoc analyses suggests drugs effective in HFrEF may also benefit HFmrEF patients, though dedicated trials are lacking 3, 6.

Common Pitfalls to Avoid

  1. Don't diagnose heart failure based on EF alone—you must have symptoms plus elevated filling pressures
  2. Don't assume static EF—repeat measurements are essential as HFmrEF is often transitional
  3. Don't withhold HFrEF therapies if true HFmrEF is diagnosed—these patients likely benefit from guideline-directed medical therapy
  4. Don't ignore the trajectory—whether EF is improving from lower values or declining from higher values matters for prognosis and management 1

Special Consideration: HF with Improved EF

If a patient previously had HFrEF (EF <40%) and now has EF 40-45%, they are classified as HFimpEF (heart failure with improved ejection fraction) and should continue all HFrEF treatments indefinitely, as discontinuation often leads to relapse 2, 1, 7.

Related Questions

What does a normal nuclear‑medicine stress test and an ejection fraction of 64% indicate?
Does an ejection fraction of 40–45% indicate heart failure with reduced ejection fraction?
Is heart failure with mildly reduced ejection fraction (EF 41–49%) still recognized and treated?
What is Heart Failure (HF) with mid-range ejection fraction (mrEF)?
Does ejection fraction (EF) increase in patients with heart failure?
What is the efficacy of pentobarbital when used for lethal injection?
Is this patient’s presentation consistent with histamine intolerance?
In a male endurance cyclist on long‑term testosterone therapy with left‑ventricular hypertrophy and increasing late gadolinium enhancement (4%→12%) on cardiac MRI, how do recreational versus competitive cycling differ, and which intensity/volume is acceptable versus unacceptable?
Is there a blood test available to diagnose Parkinson's disease?
In a prisoner presenting with fever, foul‑smelling green sputum, weight loss, cachexia, dyspnea, and a left lower lobe mass with thick, irregular walls and an air‑fluid level, are the thick irregular walls considered benign or suspicious?
In a 46-year-old man with five-year primary infertility, right testicular atrophy, left normal testis, bilateral epididymitis on ultrasound, elevated prolactin, elevated luteinizing hormone, normal follicle‑stimulating hormone, low‑normal testosterone, and a normal 46,XY karyotype without Y‑chromosome microdeletions, what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.